ONCY — Oncolytics Biotech Inc.

ONCY Q1 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash and Cash Equivalents: $15.3 million as of March 31, 2025, providing a runway through Q3 2025.
• Net Cash Used in Operating Activities: $6.5 million, down from $7.5 million in Q1 2024, reflecting lower operating expenditures.
• General and Administrative Expenses: $3 million, consistent with the prior year.
• Research and Development Expenses: $4.1 million, down from $5.7 million in Q1 2024, primarily due to reduced manufacturing and clinical trial costs.
• Net Loss: $6.7 million or $0.08 per share, compared to a net loss of $6.9 million or $0.09 per share in Q1 2024.
• Capital Access: Announced a $20 million share purchase agreement with Alumni Capital to extend financial runway.

2. Strategic Updates and Business Highlights

• CEO Search: Active search for a new CEO to lead the company and focus on clinical trial execution for pelareorep (pela).
• Clinical Progress: Positive interim results from GOBLET Cohort 4 in anal carcinoma, showing a 33% objective response rate. Cohort 5 for pancreatic cancer is currently enrolling patients.
• Breast Cancer Studies: Two randomized Phase 2 studies (IND-213 and BRACELET-1) show significant clinical benefits for pela in metastatic breast cancer, with plans for a registration-enabling study.
• Business Development: Engaging with potential partners at major conferences (JPMorgan, ASCO, BIO) to explore global and regional partnerships.

3. Forward Guidance and Outlook

• Clinical Data Sharing: Expect to present pancreatic cancer data at ASCO later this year and initial efficacy data from GOBLET Cohort 5 in 2026.
• Regulatory Pathways: Anticipate primary endpoint of progression-free survival (PFS) for the upcoming breast cancer study, with ongoing discussions with regulatory agencies regarding the pancreatic cancer program.

4. Bad News, Challenges, or Points of Concern

• Leadership Transition: The ongoing CEO search may create uncertainty during a critical period for the company.
• Regulatory Engagement: Limited recent interactions with the FDA regarding the pancreatic cancer program may pose risks in navigating registrational pathways.
• Market Competition: The evolving landscape in breast cancer treatment, particularly with the introduction of antibody-drug conjugates, may complicate the positioning of pela.

5. Notable Q&A Insights

• Trial Design for Breast Cancer: The next study is expected to focus on progression-free survival as a primary endpoint, with potential for a smaller cohort study targeting patients who have failed prior therapies, including antibody-drug conjugates.
• Business Development Focus: The company is prioritizing partnerships that can maximize the value of pela across multiple indications, particularly in breast and pancreatic cancers.
• Combination Therapies: There is ongoing exploration of combining pela with checkpoint inhibitors, especially in pancreatic cancer, where preliminary data suggest a synergistic effect.

Overall, ONCY is making significant strides in clinical development and business strategy, although challenges remain in leadership transition and regulatory navigation.